Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Background Up to half of patients with infective endocarditis (IE) require cardiac surgery. Although anaemia is common, its precise prevalence, transfusion practices and impact on outcomes in ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics ...

A new study published in the journal of Nature Scientific Reports showed that patients with end-stage renal disease (ESRD) ...

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025SAN FRANCISCO, (GLOBE NEWSWIRE) -- FibroGen, Inc.

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused ...

Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD ...